Related Experiment Video
Updated: May 30, 2025

08:30
Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots
Published on: June 2, 2015
9.3K
Tirzepatide for Congenital Generalized Lipodystrophy
Svetlana Ten1, Amrit Bhangoo2, Christoph Buettner1
1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
The New England Journal of Medicine
|January 31, 2025
Summary
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Overview of Lipid Metabolism
969
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
969

